Institute for Global Health, University College London, 30 Guildford Street, London, WC1N 1EH, UK.
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Trials. 2023 Mar 23;24(1):218. doi: 10.1186/s13063-023-07243-x.
The "Diabetes: Community-led Awareness, Response and Evaluation" (D:Clare) trial aims to scale up and replicate an evidence-based participatory learning and action cycle intervention in Bangladesh, to inform policy on population-level T2DM prevention and control.The trial was originally designed as a stepped-wedge cluster randomised controlled trial, with the interventions running from March 2020 to September 2022. Twelve clusters were randomly allocated (1:1) to implement the intervention at months 1 or 12 in two steps, and evaluated through three cross-sectional surveys at months 1, 12 and 24. However, due to the COVID-19 pandemic, we suspended project activities on the 20th of March 2020. As a result of the changed risk landscape and the delays introduced by the COVID-19 pandemic, we changed from the stepped-wedge design to a wait-list parallel arm cluster RCT (cRCT) with baseline data. We had four key reasons for eventually agreeing to change designs: equipoise, temporal bias in exposure and outcomes, loss of power and time and funding considerations.Trial registration ISRCTN42219712 . Registered on 31 October 2019.
“糖尿病:社区主导的意识、响应和评估”(D:Clare)试验旨在扩大和复制孟加拉国基于证据的参与式学习和行动循环干预措施,为人口层面的 T2DM 预防和控制政策提供信息。该试验最初设计为一项阶梯式楔形集群随机对照试验,干预措施于 2020 年 3 月至 2022 年 9 月进行。12 个集群被随机分配(1:1)在两个月进行干预,分为两步,在第 1、12 和 24 个月进行三次横断面调查进行评估。然而,由于 COVID-19 大流行,我们于 2020 年 3 月 20 日暂停了项目活动。由于风险状况的变化以及 COVID-19 大流行带来的延迟,我们从阶梯式楔形设计改为等待名单平行臂集群 RCT(cRCT),具有基线数据。我们最终同意改变设计有四个关键原因:均衡、暴露和结果的时间偏差、失去力量和时间以及资金考虑。试验注册 ISRCTN42219712。于 2019 年 10 月 31 日注册。